Fig. 2: Waterfall plot of change in liver fat content and hemoglobin A1c in individual subjects. | Nature Communications

Fig. 2: Waterfall plot of change in liver fat content and hemoglobin A1c in individual subjects.

From: A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Fig. 2

Liver fat content in panels a [n = 30], b [n = 31] and c [n = 33], and hemoglobin A1c (HbA1C) in panels d [n = 26], e [n = 29] and f [n = 32]), among subjects receiving berberine ursodeoxycholate (BUDCA) 1000 mg twice a day (BID), 500 mg BID or placebo, respectively.

Back to article page